MX2024011603A - Forma de sal cristalina de un inhibidor de shp2. - Google Patents

Forma de sal cristalina de un inhibidor de shp2.

Info

Publication number
MX2024011603A
MX2024011603A MX2024011603A MX2024011603A MX2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A MX 2024011603 A MX2024011603 A MX 2024011603A
Authority
MX
Mexico
Prior art keywords
salt form
crystalline salt
shp2 inhibitor
crystalline form
relates
Prior art date
Application number
MX2024011603A
Other languages
English (en)
Spanish (es)
Inventor
Katie Keaton Brown
Connor James Cowdrey
Aaron Keith Goodwin
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2024011603A publication Critical patent/MX2024011603A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024011603A 2022-03-23 2023-03-20 Forma de sal cristalina de un inhibidor de shp2. MX2024011603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23
PCT/IB2023/052709 WO2023180898A1 (en) 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor

Publications (1)

Publication Number Publication Date
MX2024011603A true MX2024011603A (es) 2024-09-30

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011603A MX2024011603A (es) 2022-03-23 2023-03-20 Forma de sal cristalina de un inhibidor de shp2.

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2025509818A (ja) 2025-04-11
TW202346282A (zh) 2023-12-01
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
AR128847A1 (es) 2024-06-19
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
KR20240163705A (ko) 2024-11-19
AU2023238523B2 (en) 2025-10-30
AU2023238523A1 (en) 2024-08-22
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
BR112023019479A2 (pt) Forma cristalina de um inibidor de shp2
CO2023012682A2 (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
PY1932509A (es) Inhibidores de cinasa dependientes de ciclina
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
ECSP099803A (es) Derivados de bencimidazol
ECSP055867A (es) Derivados de pirrolopirimidina
UY32582A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CO6630133A2 (es) Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
TW200942536A (en) PIM kinase inhibitors and methods of their use
UY33328A (es) "5,7-SUSTITUIDO-IMIDAZOL[1,2-c]PIRIMIDINAS"
CL2022001337A1 (es) Derivados de piridopirimidinona como antagonistas de ahr
DOP2025000216A (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek
CL2025001366A1 (es) Derivados de fenilpiperidina como inhibidores de la glutaminil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa
UY28894A1 (es) Derivados de pirimidina para tratar el crecimiento celular anómalo
AR128847A1 (es) Forma de sal cristalina de un inhibidor de shp2
CL2024003797A1 (es) Compuestos derivados de 2-oxo-1,2-dihidroquinolina que degradan bcl6, composición y uso para tratar el cancer.
AR133442A1 (es) Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de la glutamil-péptido ciclotransferasa y proteína similar a glutaminil-péptido ciclotransferasa